Assenagon Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-183,592
| Closed | -$685K | – | 1434 |
|
|
2024
Q3 | $685K | Sell |
183,592
-1,745
| -0.9% | -$6.51K | ﹤0.01% | 1168 |
|
|
2024
Q2 | $1.04M | Hold |
185,337
| – | – | ﹤0.01% | 1068 |
|
|
2024
Q1 | $971K | Sell |
185,337
-32,331
| -15% | -$169K | ﹤0.01% | 1042 |
|
|
2023
Q4 | $1.14M | Hold |
217,668
| – | – | ﹤0.01% | 1033 |
|
|
2023
Q3 | $3.43M | Buy |
217,668
+86,917
| +66% | +$1.37M | 0.01% | 651 |
|
|
2023
Q2 | $2.54M | Sell |
130,751
-43,909
| -25% | -$854K | 0.01% | 664 |
|
|
2023
Q1 | $4.96M | Buy |
174,660
+62,408
| +56% | +$1.77M | 0.02% | 554 |
|
|
2022
Q4 | $3.28M | Buy |
112,252
+34,695
| +45% | +$1.01M | 0.01% | 618 |
|
|
2022
Q3 | $2.05M | Sell |
77,557
-5,707
| -7% | -$151K | 0.01% | 687 |
|
|
2022
Q2 | $3.7M | Sell |
83,264
-4,465
| -5% | -$198K | 0.01% | 610 |
|
|
2022
Q1 | $4.34M | Buy |
87,729
+35,649
| +68% | +$1.76M | 0.01% | 530 |
|
|
2021
Q4 | $2.65M | Buy |
52,080
+9,037
| +21% | +$460K | 0.01% | 689 |
|
|
2021
Q3 | $2.4M | Buy |
+43,043
| New | +$2.4M | 0.01% | 604 |
|